메뉴 건너뛰기




Volumn 216, Issue 5, 2017, Pages 594-603

Prevalence of human papillomavirus among females after vaccine introduction-national health and Nutrition Examination Survey, United States, 2003-2014

Author keywords

HPV vaccine; Human papillomavirus; Prevalence; Vaccine effectiveness; Vaccine impact

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

EID: 85028966058     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix244     Document Type: Article
Times cited : (120)

References (36)
  • 1
    • 84873606312 scopus 로고    scopus 로고
    • Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels
    • Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175-201.
    • (2013) J Natl Cancer Inst , vol.105 , pp. 175-201
    • Jemal, A.1    Simard, E.P.2    Dorell, C.3
  • 2
    • 84907813308 scopus 로고    scopus 로고
    • Human papillomavirus vaccination: Recommendations of the advisory committee on immunization practices (ACIP)
    • Markowitz LE, Dunne EF, Saraiya M, et al; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63:1-30.
    • (2014) MMWR Recomm Rep , vol.63 , pp. 1-30
    • Markowitz, L.E.1    Dunne, E.F.2    Saraiya, M.3
  • 3
    • 84929509772 scopus 로고    scopus 로고
    • Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices
    • Petrosky E, Bocchini JA Jr, Hariri S, et al; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2015; 64:300-4.
    • (2015) MMWR Morb Mortal Wkly Rep , vol.64 , pp. 300-304
    • Petrosky, E.1    Bocchini, J.A.2    Hariri, S.3
  • 4
    • 84255198571 scopus 로고    scopus 로고
    • Recommendations on the use of quadrivalent human papillomavirus vaccine in males-advisory committee on immunization practices (ACIP), 2011
    • Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705-8.
    • (2011) MMWR Morb Mortal Wkly Rep , vol.60 , pp. 1705-1708
  • 5
    • 84904581436 scopus 로고    scopus 로고
    • Human papillomavirus vaccination coverage among adolescents, 2007-2014-United States
    • Stokley S, Jeyarajah J, Yankey D, et al. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescents, 2007-2014-United States. MMWR Morb Mortal Wkly Rep 2014; 63:620-4.
    • (2014) MMWR Morb Mortal Wkly Rep , vol.63 , pp. 620-624
    • Stokley, S.1    Jeyarajah, J.2    Yankey, D.3
  • 6
    • 84983591880 scopus 로고    scopus 로고
    • National, regional, state and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2015
    • Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:850-8.
    • (2016) MMWR Morb Mortal Wkly Rep , vol.65 , pp. 850-858
    • Reagan-Steiner, S.1    Yankey, D.2    Jeyarajah, J.3
  • 7
    • 84880198301 scopus 로고    scopus 로고
    • Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, national health and nutrition examination surveys, 2003-2010
    • Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-93.
    • (2013) J Infect Dis , vol.208 , pp. 385-393
    • Markowitz, L.E.1    Hariri, S.2    Lin, C.3
  • 8
    • 84960172818 scopus 로고    scopus 로고
    • Prevalence of HPV after introduction of the vaccination program in the United States
    • Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016; 137:e20151968.
    • (2016) Pediatrics , vol.137 , pp. e20151968
    • Markowitz, L.E.1    Liu, G.2    Hariri, S.3    Steinau, M.4    Dunne, E.F.5    Unger, E.R.6
  • 9
    • 65549109389 scopus 로고    scopus 로고
    • The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years
    • Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-35.
    • (2009) J Infect Dis , vol.199 , pp. 926-935
    • Brown, D.R.1    Kjaer, S.K.2    Sigurdsson, K.3
  • 10
    • 84855309413 scopus 로고    scopus 로고
    • Cross-protective eficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
    • Wheeler CM, Castellsagué X, Garland SM, et al; HPV PATRICIA Study Group. Cross-protective eficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10.
    • (2012) Lancet Oncol , vol.13 , pp. 100-110
    • Wheeler, C.M.1    Castellsagué, X.2    Garland, S.M.3
  • 11
    • 84908152101 scopus 로고    scopus 로고
    • Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: A repeat cross-sectional study
    • Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14:958-66.
    • (2014) Lancet Infect Dis , vol.14 , pp. 958-966
    • Tabrizi, S.N.1    Brotherton, J.M.2    Kaldor, J.M.3
  • 12
    • 84901636857 scopus 로고    scopus 로고
    • Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
    • Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110:2804-11.
    • (2014) Br J Cancer , vol.110 , pp. 2804-2811
    • Kavanagh, K.1    Pollock, K.G.2    Potts, A.3
  • 13
    • 84988530527 scopus 로고    scopus 로고
    • Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes
    • Mesher D, Soldan K, Lehtinen M, et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis 2016; 22:1732-40.
    • (2016) Emerg Infect Dis , vol.22 , pp. 1732-1740
    • Mesher, D.1    Soldan, K.2    Lehtinen, M.3
  • 14
    • 84950301776 scopus 로고    scopus 로고
    • Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013
    • Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis 2016; 22:56-64.
    • (2016) Emerg Infect Dis , vol.22 , pp. 56-64
    • Cameron, R.L.1    Kavanagh, K.2    Pan, J.3
  • 15
    • 84871636917 scopus 로고    scopus 로고
    • The national health and nutrition examination survey: Sample design, 1999-2006
    • National Center for Health Statistics
    • Curtin LR, Mohadjer L, Dohrmann S, et al. The National Health and Nutrition Examination Survey: sample design, 1999-2006. National Center for Health Statistics. Vital Health Stat 2, 2012; 1-39.
    • (2012) Vital Health Stat , vol.2 , pp. 1-39
    • Curtin, L.R.1    Mohadjer, L.2    Dohrmann, S.3
  • 16
    • 85047656089 scopus 로고    scopus 로고
    • The national health and nutrition examination survey: Sample design, 2007-2010
    • National Center for Health Statistics
    • Curtin LR, Mohadjer L, Dohrmann S, et al. The National Health and Nutrition Examination Survey: sample design, 2007-2010. National Center for Health Statistics. Vital Health Stat 2, 2013; 1-23.
    • (2013) Vital Health Stat , vol.2 , pp. 1-23
    • Curtin, L.R.1    Mohadjer, L.2    Dohrmann, S.3
  • 17
    • 84897106445 scopus 로고    scopus 로고
    • The national health and nutrition examination survey: Sample design, 2011-2014
    • National Center for Health Statistics
    • Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK, et al. The National Health and Nutrition Examination Survey: sample design, 2011-2014. National Center for Health Statistics. Vital Health Stat 2, 2014; 1-33.
    • (2014) Vital Health Stat , vol.2 , pp. 1-33
    • Johnson, C.L.1    Dohrmann, S.M.2    Burt, V.L.3    Mohadjer, L.K.4
  • 18
    • 79960882717 scopus 로고    scopus 로고
    • Prevalence of genital human papillomavirus among females in the United States, the national health and nutrition examination survey, 2003-2006
    • Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis 2011; 204:566-73.
    • (2011) J Infect Dis , vol.204 , pp. 566-573
    • Hariri, S.1    Unger, E.R.2    Sternberg, M.3
  • 19
    • 84857378878 scopus 로고    scopus 로고
    • A realtime PCR assay for HPV52 detection and viral load quantification
    • Onyekwuluje JM, Steinau M, Swan DC, Unger ER. A realtime PCR assay for HPV52 detection and viral load quantification. Clin Lab 2012; 58:61-6.
    • (2012) Clin Lab , vol.58 , pp. 61-66
    • Onyekwuluje, J.M.1    Steinau, M.2    Swan, D.C.3    Unger, E.R.4
  • 20
    • 0034209312 scopus 로고    scopus 로고
    • Design and estimation for the national health interview survey, 1995-2004
    • Design and estimation for the National Health Interview Survey, 1995-2004. Vital Health Stat 2, 2000; 1-31.
    • (2000) Vital Health Stat , vol.2 , pp. 1-31
  • 21
    • 0026345221 scopus 로고
    • Epidemiologic studies utilizing surveys: Accounting for the sampling design
    • Korn EL, Graubard BI. Epidemiologic studies utilizing surveys: accounting for the sampling design. Am J Public Health 1991; 81:1166-73.
    • (1991) Am J Public Health , vol.81 , pp. 1166-1173
    • Korn, E.L.1    Graubard, B.I.2
  • 22
    • 77249150921 scopus 로고    scopus 로고
    • Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data
    • Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am J Epidemiol 2010; 171:618-23.
    • (2010) Am J Epidemiol , vol.171 , pp. 618-623
    • Bieler, G.S.1    Brown, G.G.2    Williams, R.L.3    Brogan, D.J.4
  • 23
    • 84937691111 scopus 로고    scopus 로고
    • Income and poverty in the United States Washington, DC: US Government Printing Office P60-256(RV)
    • Proctor BD, Semega JL, Kollar MA; US Census Bureau. Current population reports. Income and poverty in the United States: 2015. Washington, DC: US Government Printing Office, 2016: P60-256(RV).
    • (2015) Current Population Reports
    • Proctor, B.D.1    Semega, J.L.2    Kollar, M.A.3
  • 24
    • 84876039831 scopus 로고    scopus 로고
    • 2010 census briefs, C2010BR-05 Accessed 12 January 2017
    • Hixon L, Hepler BB, Kim MO; US Census Bureau. The white population: 2010. 2010 census briefs, C2010BR-05. http://census.gov/content/dam/Census/library/publications/2011/dec/c2010br-05.pdf. Accessed 12 January 2017.
    • The White Population: 2010
    • Hixon, L.1    Hepler, B.B.2    Kim, M.O.3
  • 26
    • 84880145384 scopus 로고    scopus 로고
    • Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: Potential impact of human papillomavirus vaccination
    • Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103:1428-35.
    • (2013) Am J Public Health , vol.103 , pp. 1428-1435
    • Flagg, E.W.1    Schwartz, R.2    Weinstock, H.3
  • 27
    • 84995665299 scopus 로고    scopus 로고
    • Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007-2014
    • Flagg EW, Torrone EA, Weinstock H. Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007-2014. Am J Public Health 2016; 106:2211-8.
    • (2016) Am J Public Health , vol.106 , pp. 2211-2218
    • Flagg, E.W.1    Torrone, E.A.2    Weinstock, H.3
  • 28
    • 84994410098 scopus 로고    scopus 로고
    • Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community
    • Kahn JA, Widdice LE, Ding L, et al. Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. Clin Infect Dis 2016; 63:1281-7.
    • (2016) Clin Infect Dis , vol.63 , pp. 1281-1287
    • Kahn, J.A.1    Widdice, L.E.2    Ding, L.3
  • 30
    • 0022414596 scopus 로고
    • Vaccination and herd immunity to infectious diseases
    • Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature 1985; 318:323-9.
    • (1985) Nature , vol.318 , pp. 323-329
    • Anderson, R.M.1    May, R.M.2
  • 31
    • 84864528970 scopus 로고    scopus 로고
    • Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction
    • Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012; 130:e249-56.
    • (2012) Pediatrics , vol.130 , pp. e249-e256
    • Kahn, J.A.1    Brown, D.R.2    Ding, L.3
  • 32
    • 85020209481 scopus 로고    scopus 로고
    • Prevalence of genital human papillomavirus in males, United States, 2013-2014
    • Gargano J, Unger ER, Liu G, et al. Prevalence of genital human papillomavirus in males, United States, 2013-2014. J Infect Dis 2017; 215:1070-9.
    • (2017) J Infect Dis , vol.215 , pp. 1070-1079
    • Gargano, J.1    Unger, E.R.2    Liu, G.3
  • 33
    • 67651049056 scopus 로고    scopus 로고
    • Eficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women
    • Paavonen J, Naud P, Salmerón J, et al; HPV PATRICIA Study Group. Eficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14.
    • (2009) Lancet , vol.374 , pp. 301-314
    • Paavonen, J.1    Naud, P.2    Salmerón, J.3
  • 34
    • 34248365967 scopus 로고    scopus 로고
    • Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
    • Garland SM, Hernandez-Avila M, Wheeler CM, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
    • (2007) N Engl J Med , vol.356 , pp. 1928-1943
    • Garland, S.M.1    Hernandez-Avila, M.2    Wheeler, C.M.3
  • 35
    • 84928216017 scopus 로고    scopus 로고
    • Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis
    • Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80.
    • (2015) Lancet Infect Dis , vol.15 , pp. 565-580
    • Drolet, M.1    Bénard, E.2    Boily, M.C.3
  • 36
    • 85007470614 scopus 로고    scopus 로고
    • Use of a 2-dose schedule for human papillomavirus vaccination-updated recommendations of the advisory committee on immunization practices
    • Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination-updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016; 65:1405-8.
    • (2016) MMWR Morb Mortal Wkly Rep , vol.65 , pp. 1405-1408
    • Meites, E.1    Kempe, A.2    Markowitz, L.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.